Retatrutide (5mg)
The Science
What is Retatrutide?
Retatrutide is a synthetic polypeptide engineered as a single-molecule triple agonist of the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors.
The triple-receptor design extends the dual GIP/GLP-1 mechanism of tirzepatide by adding glucagon receptor activation, which contributes additional effects on energy expenditure and hepatic lipid metabolism beyond appetite suppression and insulin sensitization.
Phase 2 clinical research in obesity and type 2 diabetes has reported substantial reductions in body weight and improvements in glycemic and hepatic metabolic parameters. Retatrutide is investigational; it is not approved for any indication.
Laboratory Observations
Research-Observed Areas of Interest
Body Weight Reduction
Phase 2 trials in obesity have reported placebo-adjusted weight reductions exceeding those of single- or dual-agonist comparators, with continued weight loss across the 48-week study duration.
Glycemic Control
In type 2 diabetes research, Retatrutide has demonstrated substantial reductions in HbA1c and fasting glucose, consistent with its incretin-driven mechanism.
Hepatic Steatosis
Research in MASLD shows large reductions in liver fat content with Retatrutide, attributed to combined improvements in insulin sensitivity, weight loss, and direct glucagon-receptor effects on hepatic lipid handling.
Cardiometabolic Risk Factor Modification
Improvements in lipid profile, blood pressure, and inflammatory markers have been observed alongside weight loss in clinical research.
Mechanism of Action
How Retatrutide Works
Retatrutide engages three incretin and metabolic receptors with complementary effects on weight, glucose, and lipid handling:
GLP-1 Receptor Activation
GLP-1 receptor activation augments glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and reduces appetite via central pathways.
GIP Receptor Activation
GIP receptor activation enhances incretin-driven insulin secretion and contributes to adipose tissue insulin sensitization and lipid storage regulation, complementing GLP-1 actions on glycemic control and body weight.
Glucagon Receptor Activation
Glucagon receptor activation increases hepatic lipid oxidation and basal energy expenditure, which research suggests contributes to the magnitude of weight loss observed and to improvements in hepatic steatosis.
FAQ
Frequently Asked Questions
How does Retatrutide differ from semaglutide and tirzepatide?+
Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide adds glucagon receptor activation to the GIP/GLP-1 backbone, providing a triple-agonist mechanism with additional effects on energy expenditure and hepatic lipid metabolism.
Why include glucagon-receptor activity in a weight-loss compound?+
Glucagon-receptor activation increases hepatic fat oxidation and basal energy expenditure. Combined with the appetite-suppressing and insulin-sensitizing actions of GLP-1 and GIP, this contributes to greater observed weight loss and reductions in liver fat in research settings.
Is Retatrutide approved?+
No. Retatrutide remains an investigational compound under active clinical development and has not received regulatory approval for any indication.
Research-Only Notice
Retatrutide (5mg) is categorized by the FDA as for research-purposes-only. It is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease. The information above summarizes effects observed in laboratory studies to date and is provided strictly for scientific and educational reference.